How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

RXRX is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.21 since the market last closed. This is a 4.95% ...

Flint coding model by Recursive offers up to 130 tokens per second on an M4 Mac. The new open-source AI leverages a mixture ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

On February 24, 2026, EPA published the "Common Sense Approach to Chemical Accident Prevention Proposed Rule," which proposes revisions to the Risk Management Program to ensure regulatory consistency, ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Find out the direct holders, institutional holders and mutual fund holders for Recursion Pharmaceuticals, Inc. (RXRX).